Diagnostic Accuracy of Histoplasma Urine Antigen Assay Evaluated
By LabMedica International staff writers Posted on 29 Nov 2018 |
Image: The ALPHA Histoplasma Enzyme Immunoassay (EIA) test kit (Photo courtesy of IMMY).
Histoplasmosis is an endemic mycosis in many regions of Latin America. In the human immunodeficiency virus (HIV) infected population it manifests as progressive disseminated histoplasmosis (PDH), an entity hard to diagnose since the causative fungi, Histoplasma capsulatum, is slow growing and requires advance biosafety for its handling.
The standard of reference for PDH diagnosis is the isolation of Histoplasma capsulatum from a non-respiratory sample, typically bone marrow or peripheral blood, or the visualization of yeast-like structures in the histopathologic examination. In the USA, histoplasmosis is also endemic, and its PDH presentation is commonly diagnosed by the detection of Histoplasma urine antigen (HUAg).
Scientists at The National Institute of Medical Sciences and Nutrition Salvador Zubirán (Tlalpan, Mexico City, Mexico) conducted a multicenter, prospective, diagnostic test study in two secondary and eight tertiary-care facilities from seven states of Mexico, from December 2015 to October 2017. At least 5 mL of peripheral blood were inoculated in a BD BACTEC Myco F/ Lytic vial; for bone marrow aspirates, a similar amount (5 mL) was inoculated in a BACTEC Myco F/ Lytic and a BACTEC Peds Plus F (3 mL), and 1 mL in a Löwenstein-Jensen and Sabouraud solid media.
The team evaluated the diagnostic accuracy of IMMY ALPHA Histoplasma Enzyme immunoassay (EIA) Test Kit. The scientists included 288 cases for this analysis. From these patients, the central laboratory processed 1,068 samples: 277 blood cultures, 252 bone marrow aspirate cultures, 104 biopsies for tissue culture, 147 biopsies for the histopathologic examination, and 288 urine samples for HUAg detection. They classified 85/288 (29.5%) patients as PDH–proven, 28.2% (24/85) based on positive histopathologic examination and positive culture, 58.8% (50/85) by positive culture only and 12.9% (11/85) by positive histopathologic exam only. The sensitivity of ALPHA-HUAg was 67.1% (95% CI, 56–76.8%) and the specificity was 97.5% (95% CI, 94.3%-99.1%). The positive likelihood ratio was 27.2 (95% CI; 11.6–74.4). In 10.5% of the PDH–proven patients, a co-existing opportunistic infection was diagnosed, mostly disseminated Mycobacterium avium complex infection.
The authors concluded that ALPHA-HUAg is a useful test for the diagnosis of PDH, in patients with high level of suspicion in endemic regions for H. capsulatum, and may favor early targeted-antifungal treatment, thus improving the prognosis of these frail HIV-patients. Nevertheless, the culture-based approach should ensue simultaneously since co-infections are frequent and a negative result of ALPHA-HUAg does not discard PDH in patients from endemic regions for H. capsulatum. The study was published on November 5, 2018, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
National Institute of Medical Sciences and Nutrition Salvador Zubirán
The standard of reference for PDH diagnosis is the isolation of Histoplasma capsulatum from a non-respiratory sample, typically bone marrow or peripheral blood, or the visualization of yeast-like structures in the histopathologic examination. In the USA, histoplasmosis is also endemic, and its PDH presentation is commonly diagnosed by the detection of Histoplasma urine antigen (HUAg).
Scientists at The National Institute of Medical Sciences and Nutrition Salvador Zubirán (Tlalpan, Mexico City, Mexico) conducted a multicenter, prospective, diagnostic test study in two secondary and eight tertiary-care facilities from seven states of Mexico, from December 2015 to October 2017. At least 5 mL of peripheral blood were inoculated in a BD BACTEC Myco F/ Lytic vial; for bone marrow aspirates, a similar amount (5 mL) was inoculated in a BACTEC Myco F/ Lytic and a BACTEC Peds Plus F (3 mL), and 1 mL in a Löwenstein-Jensen and Sabouraud solid media.
The team evaluated the diagnostic accuracy of IMMY ALPHA Histoplasma Enzyme immunoassay (EIA) Test Kit. The scientists included 288 cases for this analysis. From these patients, the central laboratory processed 1,068 samples: 277 blood cultures, 252 bone marrow aspirate cultures, 104 biopsies for tissue culture, 147 biopsies for the histopathologic examination, and 288 urine samples for HUAg detection. They classified 85/288 (29.5%) patients as PDH–proven, 28.2% (24/85) based on positive histopathologic examination and positive culture, 58.8% (50/85) by positive culture only and 12.9% (11/85) by positive histopathologic exam only. The sensitivity of ALPHA-HUAg was 67.1% (95% CI, 56–76.8%) and the specificity was 97.5% (95% CI, 94.3%-99.1%). The positive likelihood ratio was 27.2 (95% CI; 11.6–74.4). In 10.5% of the PDH–proven patients, a co-existing opportunistic infection was diagnosed, mostly disseminated Mycobacterium avium complex infection.
The authors concluded that ALPHA-HUAg is a useful test for the diagnosis of PDH, in patients with high level of suspicion in endemic regions for H. capsulatum, and may favor early targeted-antifungal treatment, thus improving the prognosis of these frail HIV-patients. Nevertheless, the culture-based approach should ensue simultaneously since co-infections are frequent and a negative result of ALPHA-HUAg does not discard PDH in patients from endemic regions for H. capsulatum. The study was published on November 5, 2018, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
National Institute of Medical Sciences and Nutrition Salvador Zubirán
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA